Emerging Therapies for Rare Genetic Mitochondrial Diseases

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs. In this podcast episode, we speak with Gregory Flesher, President and CEO of Reneo to learn more about mavodelpar, the company's lead asset, which is being developed in two rare diseases, primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).